Polaris Pharmaceuticals-KY: Shareholders Approve Lifting of Director Non-Competition Restrictions
Polaris Pharmaceuticals-KY announced that its shareholders' meeting held on May 15, 2026, approved the resolution to lift the non-competition restrictions for its new directors. The approved activities include investing in or operating businesses that are the same as or similar to the company's business scope. This waiver is effective from May 15, 2026, until the directors' term concludes. The decision was made in accordance with Article 209 of the Company Act.
📋 Article Processing Timeline
- 📰 Published: May 16, 2026 at 12:57
- 🔍 Collected: May 16, 2026 at 12:57 (0 min after Published)
- 🤖 AI Analyzed: May 16, 2026 at 14:45 (1h 48m after Collected)
Announcement Date: 115/05/16
Spokesperson Date: 115/05/15
Spokesperson Time: 21:15:57
Company Code: 6550
Company Name: Polaris Pharmaceuticals-KY
Subject: Announcement of the resolution passed by the company's shareholders' meeting to lift the non-competition restrictions for new directors.
Applicable Clause: Clause 21
Date of Event: 115/05/15
Description:
1. Shareholders' meeting resolution date: 115/05/15
2. Names and titles of directors permitted to engage in competitive activities:
Directors:
Chen Xian-zhe
Digital Capital Inc. / Representative: Wei Shao-jun
Mai Investment Co., Ltd. / Representative: Cai Gao-zhong
3. Scope of permitted competitive activities:
Investing in or operating other businesses that are the same as or similar to the company's business scope.
4. Duration of permitted competitive activities: From the date of this announcement until the end of their term.
5. Resolution details (please explain the voting results in accordance with Article 209 of the Company Act):
Passed by resolution at the shareholders' meeting on May 15, 115.
6. If the permitted competitive activities involve businesses in mainland China, director names and titles (for businesses not in mainland China, please enter 'N/A'): N/A
7. Company name and position in the mainland China business: N/A
8. Address of the mainland China business: N/A
9. Business scope of the mainland China business: N/A
10. Impact on the company's financial and business operations: N/A
11. If directors invest in mainland China businesses, investment amount and shareholding ratio: N/A
12. Other matters to be noted: None
Spokesperson Date: 115/05/15
Spokesperson Time: 21:15:57
Company Code: 6550
Company Name: Polaris Pharmaceuticals-KY
Subject: Announcement of the resolution passed by the company's shareholders' meeting to lift the non-competition restrictions for new directors.
Applicable Clause: Clause 21
Date of Event: 115/05/15
Description:
1. Shareholders' meeting resolution date: 115/05/15
2. Names and titles of directors permitted to engage in competitive activities:
Directors:
Chen Xian-zhe
Digital Capital Inc. / Representative: Wei Shao-jun
Mai Investment Co., Ltd. / Representative: Cai Gao-zhong
3. Scope of permitted competitive activities:
Investing in or operating other businesses that are the same as or similar to the company's business scope.
4. Duration of permitted competitive activities: From the date of this announcement until the end of their term.
5. Resolution details (please explain the voting results in accordance with Article 209 of the Company Act):
Passed by resolution at the shareholders' meeting on May 15, 115.
6. If the permitted competitive activities involve businesses in mainland China, director names and titles (for businesses not in mainland China, please enter 'N/A'): N/A
7. Company name and position in the mainland China business: N/A
8. Address of the mainland China business: N/A
9. Business scope of the mainland China business: N/A
10. Impact on the company's financial and business operations: N/A
11. If directors invest in mainland China businesses, investment amount and shareholding ratio: N/A
12. Other matters to be noted: None
FAQ
What was decided at the shareholders' meeting of Polaris Pharmaceuticals-KY?
The shareholders' meeting approved the lifting of non-competition restrictions for new directors.
Who are the directors permitted to engage in competitive activities?
The directors permitted are Chen Xian-zhe, Digital Capital Inc. (represented by Wei Shao-jun), and Mai Investment Co., Ltd. (represented by Cai Gao-zhong).
What kind of competitive activities are permitted?
Directors are permitted to invest in or operate businesses that are the same as or similar to the company's business scope.
What is the duration of the permitted non-competition waiver?
The waiver is effective from May 15, 2026, until their term as director ends.